Mr. Thomas Fairfull reports

FSD PHARMA AND SCICANN THERAPEUTICS LAUNCH CLINICAL RESEARCH PROGRAM IN ISRAEL

FSD Pharma Inc. has launched a clinical research collaborative program in Israel, via its strategic research and development partner, SciCann Therapeutics Inc.

This comprehensive clinical research program will be executed through SciCann's strategic alliance and collaboration agreement with Mor Research Applications Ltd. -- the technology transfer office and commercial arm of Clalit Healthcare Services, Israel's largest medical insurer and health care provider, which operates a network of 14 full-scale hospitals throughout Israel, employs over 9,000 physicians and serves the health care needs of over 50 per cent of Israel's population.

As announced previously, FSD Pharma has secured the exclusive licensing rights for the manufacturing and distribution of SciCann's line of proprietary, patent-pending, cannabinoid-based and indication-specific products in Canada.

Under the strategic alliance agreement with Mor, FSD Pharma and SciCann will execute a series of rigorous, randomized, placebo-controlled clinical studies to demonstrate the safety and efficacy of these products, in order to bring to market advanced and innovative cannabinoid-based products that are backed up by solid clinical data achieved through the highest standards of rigorous and objective clinical research typical for the development process of pharmaceutical products.

Zeeshan Saeed, executive vice-president and director of FSD Pharma, stated, "The launch of this clinical study collaboration program in Israel further demonstrates our focus and commitment to bringing disruptive science-based cannabinoid therapies to Canadian patients, and provide them with innovative cannabis products that have been tested and verified in rigorous clinical studies for the highest level of safety and efficacy."

Dr. Zohar Koren, co-founder and chief executive officer of SciCann, stated: "We are thrilled and excited to launch this strategic alliance and clinical research collaboration program with Mor Research Applications. Mor has gained substantial experience and proven track record in recent years in the efficient design and execution of large-scale clinical studies with cannabinoid-based products for various hard-to-treat diseases such as GVHD (graft versus host disease), ulcerative colitis, Crohn's disease and more. Mor is the perfect strategic partner to enable the execution of a series of proof-of-concept rigorous clinical studies with our line of proprietary indication-specific cannabinoid-based products. We are looking forward eagerly to generating a large pool of much needed clinical data and hard evidence for the potential of cannabinoid-based therapies to treat a wide range of debilitating and hard to treat diseases, results that are much awaited by the global medical and clinical community of researchers in this unique field."

Warrants issued

In connection with certain consultant agreements entered into by FSD Pharma, it has issued 2.25 million warrants for Class B subordinate voting shares at an exercise price of 13 cents. The warrants expire one year from the date of issuance and include all required statutory hold periods.

About FSD Pharma Inc.

FSD Pharma, through its wholly owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) having received its cultivation licence on Oct. 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ont., approximately an hour's drive from Toronto, FV Pharma management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts, and research and development.

We seek Safe Harbor.